-
May 21, 2026, 3:04 pm64 ptsAn investigational obesity drug from Eli Lilly cleared important endpoints in a late-stage trial, the company said Thursday, by helping patients lose up to 30 percent of their body weight. Lilly said that a once-weekly injection of retatrutide met the primary endpoint in a phase 3…
Welcome to Politomix -- the political news wire where left, right and center mix.
Politomix aggregates the day's political news on the web and your mobile device.






